Many Americans are taking GLP1 medications, which include weight loss and diabetes medications Ozempic and Wegovy.

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

A Howard County man is suing Novo Nordisk, alleging Ozempic caused him to go blind after using the drug to treat diabetes. He seeks damages in court.

The decision came in response to a February lawsuit from a compounding industry group against the FDA's decision that there ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug ...

A man who took Ozempic and then became legally blind is suing the manufacturer, arguing it should have warned patients that ...

The FDA has issued a warning about counterfeit Ozempic medications, sharing the lot numbers and serial numbers of products ...

A U.S. study of over 500 youth aged 14–24 found high awareness but widespread hesitation about using semaglutide for weight ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...